Efficacy and Safety of Unani Formulation in Loss of Appetite

Aims and Objectives: Loss of appetite (LOA) impacts individual well-being and quality of life. It can contribute to weight loss and nutritional deficiencies, and associated poor healthcare outcomes, including increased mortality. This study presents the efficacy and safety of Unani pharmacopeia formulation. Habb-e-TurshMushtahi in loss of appetite (Anorexia).

Study Design: Open-labelled, single arm, clinical trial.

Materials and Methods: The study was conducted on 100 patients having the complaint of loss of appetite; Patients of either sex in the age group of 18 to 65years and decreased appetite with SNAC ≤14 were included in the study. The treatment was given for two weeks and safety assessment was done before and after end of treatment. P-value 0.05 was considered significant.

Results: Females were almost double than men who were suffered with the disease. The considered parameters show a good response p < 0.05 after the intervention of Unani pharmacopoeial formulation in both genders. In case of safety parameters, no significance p>0.05 has been seen for pathological and biochemical investigations.

Conclusion: The management for the loss of appetite can be easily treated with the unani drug which is effective for the rapid relief without any adverse effect.